Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belimumab for Treatment of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

NCT05604742 is registered in ClinicalTrials.gov with xuna as lead sponsor.

NCT NCT05604742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05604742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belimumab for Treatment of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Lead sponsor
xuna
Phase
Phase 1/2
Overall status
Withdrawn
Start date
January 1, 2022
Completion date
December 31, 2024
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cgvhd